Edith A. Perez

Increased Incidence of Loco-Regional Recurrences Among African American Women with Terminal Stage Breast Cancer (2008)

Gerardo Colón-Otero, Sherry King, Vandelyn Smith, Carolyn Bieber, Julia Crook, Lawrence A. Solberg, ...

A prospective analysis of women with terminal breast cancer admitted to CHNE from November 2006-August 2007 evaluated anecdotal observations that African American (AA) women are likelier than...

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17 (2005)

Goss, Paul E., Ingle, James N., Martino, Silvana, Robert, Nicholas J., Muss, Hyman B., Piccart, Martine J., ...

Background: Most recurrences in women with breast cancer receiving 5 years of adjuvant tamoxifen occur after 5 years. The MA.17 trial, which was designed to determine whether extended adjuvant...

RESPONSE: Re: HER2 Testing in the Real World (2003)

Perez, Edith A., Jenkins, Robert B.

Concordance Between Local and Central Laboratory HER2 Testing in the Breast Intergroup Trial N9831 (2002)

Roche, Patrick C., Suman, Vera J., Jenkins, Robert B., Davidson, Nancy E., Martino, Silvana, Kaufman, Peter A., ...

The efficacy of trastuzumab for metastases coupled with the relatively poor prognosis of patients with node-positive, HER2-positive breast cancer has led to the evaluation of trastuzumab as an...

Cisplatin Dose Intensity in Non-Small Cell Lung Cancer: Phase II Results of a Day 1 and Day 8 High-Dose Regimen (1989)

Gandara, David R., Wold, Howard, Perez, Edith A., Deisseroth, Albert B., Doroshow, J., Meyers, F., ...

Between October 1985 and March 1987, 92 patients were registered on a phase II study of the Northern California Oncology Group investigating the importance of dose intensity in the treatment of...

Safety of aromatase inhibitors in the adjuvant setting

Perez, Edith A.

The third-generation aromatase inhibitors (AIs) letrozole, anastrozole, and exemestane are replacing tamoxifen as adjuvant therapy in most postmenopausal women with early breast cancer. Although AIs...

p120 catenin induces opposing effects on tumor cell growth depending on E-cadherin expression

Soto, Edwin, Yanagisawa, Masahiro, Marlow, Laura A., Copland, John A., Perez, Edith A., Anastasiadis, Panos Z.

p120 catenin regulates the activity of the Rho family guanosine triphosphatases (including RhoA and Rac1) in an adhesion-dependent manner. Through this action, p120 promotes a sessile cellular...

Comprehensive Diagnostic Program for Medically Underserved Women With Abnormal Breast Screening Evaluations in an Urban Population

Palmieri, Frances M., Deperi, Elizabeth R., Mincey, Betty A., Smith, Judith A., Wen, Lonnie K., Chewar, Deborah M., ...

OBJECTIVE: To institute a patient navigator program for underinsured women to eliminate delays in diagnostic resolution of abnormal screening mammograms, provide services for abnormalities noted...

Concurrent Doxorubicin Plus Docetaxel Is Not More Effective Than Concurrent Doxorubicin Plus Cyclophosphamide in Operable Breast Cancer With 0 to 3 Positive Axillary Nodes: North American Breast Cancer Intergroup Trial E 2197

Goldstein, Lori J., O'Neill, Anne, Sparano, Joseph A., Perez, Edith A., Shulman, Lawrence N., Martino, Silvana, ...

Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features

Goldstein, Lori J., Gray, Robert, Badve, Sunil, Childs, Barrett H., Yoshizawa, Carl, Rowley, Steve, ...

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100

Schneider, Bryan P., Wang, Molin, Radovich, Milan, Sledge, George W., Badve, Sunil, Thor, Ann, ...